Quick Facts

• Supports relief from the sensation of spinning or dizziness (vertigo).
• An option for addressing symptoms of motion sickness.
• Used in the management of certain vestibular system issues.

Prevomit FT is a therapeutic agent used to support individuals experiencing specific symptoms. Its primary function is in the symptomatic management of vertigo, which involves a sensation of spinning or loss of balance. This condition is often associated with diseases affecting the inner ear or vestibular system, where this medication can be a part of the clinical management plan.

Additionally, Prevomit FT is used as a treatment option for the prevention and symptomatic control of motion sickness. This may include helping to address associated discomforts such as nausea and vomiting linked to travel or motion. It is most effective when administered prior to the onset of symptoms.

All individuals considering this therapy should receive appropriate medical guidance. This medication serves as a supportive measure to help patients manage specific discomforts and maintain balance related to these conditions. It is available by prescription for managing vestibular-related symptoms and over-the-counter for the prevention of motion sickness.

Who Can and Cannot Use Prevomit FT?

The eligibility profile for Prevomit FT (Domperidone) is strictly defined by regulatory authorities to manage patient risk, primarily concerning cardiovascular health. Use is contraindicated (must not be used) in several patient populations.

Absolute Contraindications Include:

• Patients with moderate or severe hepatic impairment (liver dysfunction) or significant electrolyte disturbances.
• Individuals with pre-existing cardiac conditions, such as congestive heart failure, or a known prolongation of cardiac conduction intervals (QTc).
• Patients with specific gastrointestinal conditions, including hemorrhage, mechanical obstruction, or perforation, where increasing gut motility would be harmful.
• Concurrent use of strong CYP3A4 inhibitors or other medicines known to prolong the QT interval.

Eligibility Restrictions: Use is generally authorized for adults and adolescents (typically 12 years old and 35 kg). Use is not recommended in children under 12 years of age or during pregnancy and breastfeeding. Patients with severe renal impairment must only use the medicine with an officially documented reduction in dosing frequency and under regular review, as stated in regulatory product information. Use in older adults requires caution due to a higher observed risk of ventricular arrhythmias.

Interactions with other medicines and products

Prevomit FT is contraindicated with medicinal products that fall into two critical interaction categories: Potent CYP3A4 Inhibitors and Medicines that Prolong the QTc Interval. The co-administration of potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) is strictly prohibited because these agents reduce the active drug's clearance, resulting in a multi-fold increase in plasma concentrations. This pharmacokinetic interaction significantly elevates the risk of serious cardiac events.

Simultaneously, co-administration with other QTc-prolonging medicines (e.g., amiodarone, pimozide, citalopram) is formally contraindicated due to a pharmacodynamic additive effect on cardiac electrical activity. The regulatory labeling also specifies caution with drugs that induce bradycardia or hypokalaemia, as these conditions increase proarrhythmic potential.

Food, Substances, and Administration Timing

The product label notes interactions with substances that affect gastric acidity, such as antacids or antisecretory agents. These agents lower the oral bioavailability of the drug, leading to reduced plasma concentration. To counteract this, a timing separation rule is mandated: these substances must not be taken simultaneously. Furthermore, the consumption of grapefruit juice or sour oranges is advised to be avoided due to their ability to inhibit CYP3A4. The elimination of the active drug is dependent on liver function, making the product formally contraindicated in patients with moderate to severe hepatic impairment.

The biological action of Domperidone (Prevomit FT) is exerted through the antagonism of dopamine signaling, specifically targeting pathways outside the brain to modulate both emetic signaling and the functional movement of the digestive system.

Peripheral D2 Receptor Blockade and Emetic Signaling

This domain covers the mechanistic pathway modulation via peripheral D2 receptor blockade by addressing the molecular targets responsible for sensing and relaying triggers for emesis. The mechanism involves the targeted antagonism of Dopamine D2 receptors located in the chemoreceptor trigger zone (CTZ), a sensory area situated outside the blood-brain barrier. By blocking D2 activation in this peripheral region, the mechanism directly suppresses the afferent signals that would normally travel to the brain's vomiting center, leading to the modulation of the physiological reflex.

Enhancement of Gastrointestinal Propulsive Function

The second domain focuses on the enhancement of gastrointestinal propulsive function within the upper digestive system. Here, the antagonism of D2 receptors on enteric neurons (myenteric plexus) acts to remove dopamine's natural inhibitory control over gut function. This disinhibition indirectly facilitates the local release of acetylcholine (ACh), a neurotransmitter that stimulates muscle contraction, which results in enhanced and coordinated smooth muscle contractions and subsequent acceleration of gastric emptying and increased lower esophageal sphincter (LES) pressure.

How to Use Prevomit FT: Administration Guidelines

Prevomit FT is an anti-emetic medication containing the active substance domperidone, administered exclusively through the oral route. Its specific formulation as an Orally Disintegrating Tablet (ODT) dictates the primary procedural steps for use. The tablet should be placed directly onto the tongue where it dissolves rapidly, allowing it to be swallowed with saliva, and does not require water for administration.

Standard Dosing and Timing

The standard adult dose is 10 mg per administration, which may be taken up to three times a day (TID), resulting in a strict maximum daily dose of 30 mg. To ensure optimal absorption, the medication must be administered before meals (pre-prandially). If a dose is missed, individuals should not take an extra dose to compensate; instead, the next scheduled dose should be taken at its proper time.

Duration and Population Constraints

Treatment with Prevomit FT is restricted to the shortest possible duration, and generally should not exceed seven consecutive days. The necessity for continued treatment must be formally re-evaluated after this one-week limit. Specific adjustments to the regimen are required for certain populations. For patients with moderate-to-severe renal impairment, the dosing frequency must be officially reduced. Additionally, cautious use of the lowest effective dose is advised for older adults.

Research evidence / Overview of studies for Prevomit FT

Evidence for Symptomatic Relief of Acute Nausea and Vomiting

Research exploring the drug's application in contexts of sickness has primarily been conducted through short-term Randomized Controlled Trials (RCTs) and subsequent meta-analyses. These studies were used in research exploring how symptoms change over time, focusing on outcomes related to physical discomfort and episodic or acute changes associated with nausea and vomiting. The study populations were mainly adults and adolescents who met specific criteria for age and body weight.

Regulatory reviews describe the body of research as contributing to understanding symptom patterns related to this acute, short-term use in the populations studied. What remains uncertain is the research profile for its use in children younger than 12 years; official reviews concluded that data for this specific group were insufficient. Furthermore, the evidence contributes to understanding symptom patterns only over short observation periods, meaning long-term effects are not fully established for this type of acute relief.

Research on Gastrointestinal Motility and Functional Disorders

Research into Domperidone's activity was studied for conditions marked by functional limitations in the upper digestive tract. The evidence base here is composed of specialized open-label trials and compassionate use protocols for access. These studies focused on adults with conditions characterized by fluctuating or episodic manifestations, such as gastroparesis, where symptoms may vary in intensity and severity.

Findings describe patterns observed in these studies, particularly for patients whose symptoms were refractory (meaning they did not respond to initial treatments). Evidence is limited for general, non-severe GI symptoms, and the research often describes treatment scenarios under specific protocols, meaning results apply only to the populations studied.

What Research Gaps and Uncertainties Remain

Studies help show what has been observed so far, but the evidence highlights what is known and what is still uncertain. Follow-up durations were limited across many trials, particularly for long-term use in chronic conditions. Furthermore, comparative evidence with other treatments is limited, as studies primarily compared the drug to placebo. Research does not determine whether an individual will respond similarly, and all study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Effect of domperidone on insufficient lactation in puerperal women: a systematic review and meta-analysis of randomized controlled trials
2. Drug Safety Update - GOV.UK (Confirms regulatory restriction for children under 12 and evidence status in that population)

Common questions about Prevomit FT (FAQ)

Q: What are the different strengths or dosages of Prevomit FT available?

Official product information typically describes the oral dosage form of the active ingredient, Domperidone, as a 10 mg tablet. Some regulatory guidance notes that older or higher doses may be restricted or no longer generally recommended by health authorities.

Q: What should I do if I accidentally take too much Prevomit FT?

If an overdose is suspected, contact a healthcare professional or emergency services immediately. Regulatory documents state that signs of overdose may include agitation, changes in consciousness, drowsiness, and unusual, uncontrolled movements. Treatment, as described in regulatory documents, is typically supportive and aimed at managing the symptoms that may occur.

Q: Does Prevomit FT interact with alcohol?

Official product information often includes a warning about limiting or avoiding the consumption of alcohol while taking this medication. This is because alcohol may potentially make some of the known side effects, such as drowsiness or an increased risk of an irregular heartbeat, worse.

How to Store and Dispose of Prevomit FT?

Prevomit FT (Domperidone Orally Disintegrating Tablet) must be stored according to specific regulatory requirements to maintain its stability.

Storage Conditions

️ Disposal and Safety

Prevomit FT must be kept out of the sight and reach of children.

Unused or expired product must not be thrown away in household waste or wastewater. Disposal must follow local regulatory procedures, often via a designated drug take-back program or pharmacy guidance.